Replimune Group Inc., a clinical-stage biotechnology company focused on developing innovative oncolytic immunotherapies, has announced a scheduled Type A meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting is to discuss the complete response letter $(CRL)$ received for the company's Biologics License Application (BLA) for RP1 in combination with nivolumab, intended for the treatment of advanced melanoma. Replimune has submitted a briefing book addressing the FDA's concerns, including prior agreements on patient population and PD-1 resistance criteria, as well as additional data analyses. The company aims to resolve these issues swiftly to secure accelerated approval for RP1, emphasizing the urgent need for new treatment options in the melanoma community. The outcome of this meeting is critical, as without accelerated approval, the continuation of the RP1 program, particularly the phase 3 confirmatory trial, may not proceed.